NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Karyopharm Therapeutics Inc (NASDAQ: KPTI)
KPTI Technical Analysis
5
As on 26th Feb 2025 KPTI STOCK Price closed @ 9.83 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.05 & Strong Buy for SHORT-TERM with Stoploss of 1.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KPTISTOCK Price
Open | 8.78 | Change | Price | % |
High | 10.25 | 1 Day | 9.26 | 1624.56 |
Low | 8.30 | 1 Week | 9.21 | 1485.48 |
Close | 9.83 | 1 Month | 9.16 | 1367.16 |
Volume | 541220 | 1 Year | 8.61 | 705.74 |
52 Week High 1.66 | 52 Week Low 0.59 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
NVDA | 131.28 | 3.67% |
LCID | 2.25 | -13.79% |
SMCI | 51.11 | 12.23% |
ENVB | 2.30 | 94.92% |
LMDX | 0.02 | 0.00% |
AKTS | 0.04 | 0.00% |
TSLA | 290.80 | -3.96% |
ADTX | 0.08 | 0.00% |
GERN | 1.61 | -32.07% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
KPTI Daily Charts |
KPTI Intraday Charts |
Whats New @ Bazaartrend |
KPTI Free Analysis |
|
KPTI Important Levels Intraday
RESISTANCE | 13.59 |
RESISTANCE | 12.38 |
RESISTANCE | 11.64 |
RESISTANCE | 10.89 |
SUPPORT | 8.77 |
SUPPORT | 8.02 |
SUPPORT | 7.28 |
SUPPORT | 6.07 |
KPTI Forecast February 2025
4th UP Forecast | 10.99 |
3rd UP Forecast | 10.62 |
2nd UP Forecast | 10.39 |
1st UP Forecast | 10.16 |
1st DOWN Forecast | 9.5 |
2nd DOWN Forecast | 9.27 |
3rd DOWN Forecast | 9.04 |
4th DOWN Forecast | 8.67 |
KPTI Weekly Forecast
4th UP Forecast | 10.35 |
3rd UP Forecast | 10.18 |
2nd UP Forecast | 10.08 |
1st UP Forecast | 9.98 |
1st DOWN Forecast | 9.68 |
2nd DOWN Forecast | 9.58 |
3rd DOWN Forecast | 9.48 |
4th DOWN Forecast | 9.31 |
KPTI Forecast2025
4th UP Forecast | 28.6 |
3rd UP Forecast | 22.58 |
2nd UP Forecast | 18.86 |
1st UP Forecast | 15.14 |
1st DOWN Forecast | 4.52 |
2nd DOWN Forecast | 0.8 |
3rd DOWN Forecast | -2.92 |
4th DOWN Forecast | -8.94 |
Karyopharm Therapeutics Inc ( NASDAQ USA Symbol : KPTI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
KPTI Other Details
Segment | EQ | |
Market Capital | 414102688.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
KPTI Address
![]() |
KPTI Latest News
KPTI Business Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service